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with Acute Lymphoblastic Leukemia in Second
Complete Remission: Similar Outcomes in Recipients
of Unrelated Marrow and Umbilical Cord Blood versus
Marrow from HLA Matched Sibling Donors
Angela R. Smith, K. Scott Baker, Todd E. DeFor, Michael R. Verneris, John E. Wagner,
Margaret L. MacMillanTransplant decisions for children with acute lymphoblastic leukemia (ALL) in second complete remission
(CR2) are often based on the type of available donor. In many cases, allogeneic hematopoietic cell
transplantation (HCT) is considered only if a human leukocyte antigen (HLA) matched sibling donor
(MSD) is available. The role of unrelated donor (URD) HCT in this patient population is not well established.
As advances in supportive care and donor selection have improved, the use of URD HCT in such patients
should be reevaluated. We analyzed the outcomes of 87 consecutive children with ALL in CR2 who
underwent allogeneic HCTat the University of Minnesota between 1990 and 2007. Donor sources included
MSD bone marrow (n 5 32), well and partially matched (M, n 5 18) and mismatched (MM, n 5 16) URD
bone marrow and URD umbilical cord blood (UCB, n5 21). Although the incidence of neutrophil recovery
was similar in all groups, the overall incidence of grades II-IV acute graft-versus-host disease (aGVHD) and
chronic GVHD (cGVHD) was 37% and 9%, respectively, with a higher incidence of aGVHD in recipients of
URD grafts. Leukemia-free survival (LFS) at 5 years was lower in recipients of MM-URD grafts, but was
comparable in all other groups. Although relapse at 5 years was highest in recipients of MSD (50%), results
were not significantly different compared to recipients of M-URD (17%), MM-URD (6%), and UCB (33%)
(P 5 .17). The development of grades II-IV aGVHD and a first remission .3 years were associated with
a lower risk of relapse (relative risk [RR] 0.2, P 5 .03; RR 0.2. P 5 .01 respectively). Together, these results
support the continued investigation of URD HCT for ALL in CR2, and suggest the timing of HCT in these
children should be based primarily on the risk of relapsewith conventional chemotherapy and not on the type
of donor available.
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with standard chemotherapy, 20% to 25% will
ultimately relapse [1]. Salvage therapy for recurrent
ALL is often not curative [2]. Intensive reinduction
chemotherapy will result in a second complete
remission (CR2) in .70% of patients [3,4]; however,
the optimal strategy for long-term survival remains
unclear. Potential treatment options are maintenance
chemotherapy or allogeneic hematopoietic cell trans-
plantation (HCT) using human leukocyte antigen
(HLA) matched sibling donors (MSD) or HLA com-
patible alternate (HLA mismatched related or HLA
matched [M]/mismatched [MM] unrelated) donors.
Prospective and retrospective studies have suggested
a survival advantage in MSD recipients compared to
those treated with maintenance chemotherapy [3,5-10].
Biol Blood Marrow Transplant 15:1086-1093, 2009 1087HCT for Pediatric ALL in CR2In 1999, Boulad et al. [3] reported a series of 75 children
with ALL in CR2 treated with either HCT using an
MSD bone marrow (n 5 38) or chemotherapy (n 5
37). LFS was significantly better at 5 years in the trans-
planted group (62% and 26%, respectively [P 5 .03]),
principally because of a reduced risk of relapse after
HCT (19% versus 67% [P 5 .01]). These results
were independent of the length of first remission, char-
acteristics at diagnosis, and intensity of prior treatment
[3]. Similarly, in a collaborative study between the
Children’s Oncology Group and the Center for Inter-
national Blood and Marrow Transplant Research
(CIBMTR), Eapen et al. [10] performed a retrospective
analysis in 374 children with ALL in CR2 after a mar-
row relapse who received either an MSD HCT (n 5
186) or maintenance chemotherapy (n5 188). Signifi-
cantly better LFS was observed in transplant recipients
who had been treated with total body irradiation (TBI)
and had a history of early relapse (\36months after di-
agnosis). Despite the limitations of retrospective stud-
ies, the general practice has been to offer early
allogeneic HCT to those children with ALL in CR2
for whom an MSD is available [3,5-10].
With the limited availability of suitable related
donors, we and others have explored the safety and
efficacy of alternate sources of hematopoietic stem
cells (HSC) for transplantation. Data are emerging
that suggest alternate donor HCT may offer a long-
term survival advantage, particularly in those children
with ALL in CR2 with early or very early bonemarrow
(BM) relapse compared to those who received chemo-
therapy [11]. Although some centers are focused on the
use of haploidentical related donors, the vast majority
of alternate donor transplants in children are from
adult volunteer unrelated donors who are HLA M
(M-URD) or 1 antigen MM (MM-URD) and partially
matched umbilical cord blood (UCB) (personal com-
munication, CIBMTR). The incidence of treatment-
related mortality (TRM) has historically been high
with alternate donor transplants, but recent improve-
ments in donor selection and supportive care warrant
a reexamination of the outcomes. The aim of this
single-center study was to compare the results of
MSD and alternate donor HCT in children with
ALL in CR2 and to assess risk factors that might po-
tentially influence transplant outcomes.MATERIALS AND METHODS
Study Design
Outcomes were retrospectively evaluated in 87
consecutive children (\18 years of age at the time of
HCT) with ALL in CR2 who underwent allogeneic
HCT at the University of Minnesota between 1990
and 2007. Complete remission was defined morpho-
logically as #5% bone marrow blasts immediatelyprior to HCT. All treatment protocols were reviewed
and approved by the institutional review board at the
University of Minnesota, and all patients/guardians
provided signed informed consent.
Stem cell sources included HLA MSD BM, URD
BM, and unrelated UCB. For the UCB units, patients
anddonorswere typed forHLA-Aand -B at the antigen
level and for -DRB1 at the allele level. Elevenweremis-
matched at 1 HLA locus and 8 were mismatched at 2
HLA loci. For the other unrelated donors, patients
and donors had antigen level typing at HLA-A and -B
and allele level typing at HLA-DRB1 until June
2005, when testing at the allele level for all loci was im-
plemented. All matched sibling donors had antigen
level typing at HLA-A, -B, and -DRB1 unless adequate
family typing was not available to determine haplo-
types, in which case allele level DNA typing was
performed at all loci. Prospective allele level typing
for HLA-C was incorporated for all donor sources
beginning in June 2004. Based on the recent report
byWeisdorf et al. [12], aimed at standardizing interpre-
tations of retrospective analyses in URD transplanta-
tion, we divided our cohort into the following groups:
HLAMSD (n5 32),M-URD (n5 18; 1 well-matched
and 17 partially matched), MM-URD (n 5 16), and
UCB (n 5 21).Preparative Therapy and Supportive Care
All patients received a cyclophosphamide (Cy,
60-120 mg/kg) and TBI (1320-1375 cGy) containing
regimen, but 20MSD, 3M-URD, and 4MM-URDre-
cipients also received etoposide (VP16, 30 mg/kg) and
7 UCB recipients also received fludarabine (Flu,
75 mg/kg). Prophylaxis for acute graft-versus-host dis-
ease (aGVHD) always included cyclosporin A (CsA)
with some receivingmethotrexate (MTX, n5 56), my-
cophenolate mofetil (MMF, n5 7), methylprednisone
(MP, n5 14) or T cell depletion (n5 10). All patients
who received T cell-depleted grafts (n5 10) were par-
ticipants in local clinical trials.
Patientswerehospitalized in single rooms ventilated
with high-efficiency particulate air filtration systems.
Patients at high risk for recurrence of herpes simplex
virus (HSV) (titer$1:8) receivedprophylactic acyclovir.
Patients athigh riskof cytomegalovirus (CMV) reactiva-
tion (recipient or donor with a titer $1:8) received
prophylactic high-dose acyclovir until day 100. Docu-
mented CMV reactivation or infection was treated
with ganciclovir with or without .v. immunoglobulin.
Broad-spectrum antibiotics were administered for fever
during aplasia, and antifungals were added for persistent
fever unresponsive to antibiotic therapy. All patients re-
ceived fluconazole for prophylaxis of yeast infections for
100 days, trimethoprim-sulfamethoxazole for prophy-
laxis of Pneumocystis (carinii) jiroveci after engraftment
for 12 months after transplantation, and antibiotic
1088 Biol Blood Marrow Transplant 15:1086-1093, 2009A. R. Smith et al.prophylaxis (penicillin, gatifloxacin, or levofloxacin) for
Gram-positive organisms during the treatment of
GVHD. Intravenous granulocyte-colony stimulating
factor (G-CSF) (5 mg/kg/day) was administered daily
until neutrophil engraftment.Outcome Endpoints and Definitions
Study endpoints included neutrophil engraftment,
aGVHD (grades II-IV and grades III-IV), chronic
GVHD(cGVHD),LFS, relapse, andTRM.Neutrophil
engraftment was defined as the first of 3 consecutive
days of an absolute neutrophil count (ANC) .0.5 
109/L. Primary graft failure was defined as failure to
achieve an ANC .0.5  109/L by day 142 or date of
death (if after day121). Secondary graft failure was de-
fined as primary engraftment followed by a decrease in
the ANC to\0.5 109/Lwithout recovery until a new
stem cell infusion is required or the patient died.
aGVHD and cGVHD was evaluated and graded
according to previously published criteria, with histo-
pathologic confirmation when possible [13,14]. All
patients with engraftment were considered evaluable
for GVHD. LFS was defined as the time from trans-
plant (day 0) until disease recurrence, death, or last pa-
tient contact, whichever came first. Survival was
defined as the time from transplant day 0 until death
or last contact. Relapse was defined as a recurrence of
ALL after HCT. TRMwas defined as death in the first
100 days after HCT for any reason other than relapse.Statistical Analysis
Patient and transplant characteristics by donor
type were analyzed using the chi-square test for cate-
goric data and the Wilcoxon rank-sum test for contin-
uous data. The cumulative incidence of neutrophil
recovery was calculated by treating patients without
an ANC .0.5  109/L at day 42 or with autologous
marrow reconstitution as primary graft failures. The
cumulative incidence of aGVHD and cGVHD,
TRM, and relapse were calculated by treating deaths
from other causes as competing risks [15]. LFS was
estimated by the Kaplan-Meier method [16]. Event
times were measured from the date of transplantation
to the event or the date of last contact. Statistical com-
parisons of the time-to-event curves were completed
by the log-rank test.
Proportional hazards regression modeling was
used for multiple regression analysis with Cox regres-
sion and the Gray and Fine competing hazards method
as appropriate [17,18]. Variables considered in the
models included the main effect variable of donor
type (MSD versus M-URD versus MM-URD versus
UCB), along with conditioning regimen, GVHD
prophylaxis, age at diagnosis and transplant, sex,
CMV serostatus, aGVHD as a time-dependentvariable, length of first remission, and type of ALL
(T cell versus B cell).RESULTS
Patient Characteristics
Table 1 shows demographic and treatment charac-
teristics by stem cell source. Although there was no sig-
nificant difference between the groups with respect to
age at diagnosis, type of ALL (pre-B cell versus T cell),
length of CR1, age at transplant, sex, CMV status or
cell dose, the median length of follow-up among survi-
vors was shorter in the UCB group, MM-URD trans-
plants were more frequent prior to 1999, and UCB
transplants were more likely to have occurred after
1999 (P \ .01). Although all patients received Cy
and TBI, recipients of MSD marrow were more likely
to receive VP16 and recipients of UCB were more
likely to receive Flu as part of their conditioning
(P \ .01). Most patients transplanted with marrow
received CsA/MTX for GVHD immunoprophylaxis,
and most transplanted with UCB received CsA/
MMF. T cell depletion of URD marrow occurred in
3% of MSD, 28% of M-URD, and 25% of MM-URD
transplants (P\ .01).
Hematopoietic Recovery and Engraftment
Rates of neutrophil engraftment were similar
among HSC sources. The incidence of neutrophil re-
covery by day 142 was 97% (95% confidence interval
[CI] 91%-100%) in recipients of MSD, 100%
in recipients of M-URD, 86% (95% CI 69%-100%)
in recipients of MM-URD, and 95% (95% CI
86%-100%) in recipients of UCB (P 5 .28). Time to
neutrophil recovery was also similar between the
HSC sources, with a median of 25 days (range: 13-38
days), 24 days (range: 11-34 days), 25 days (range: 12-
32 days), and 23 days (range: 9-35days) in the HLA
MSD,M-URD,MM-URD, and UCB groups, respec-
tively (P5 .76). Primary graft failure occurred in 4 pa-
tients (MSD [n 5 1], MM-URD [n 5 2], and UCB
[n 5 1]), and secondary graft failure occurred in 3 pa-
tients (M-URD[n52] andMM-URD[n51]).There-
fore, the probability of neutrophil engraftment was
97% (95% CI 91%-100%) in the HLA MSD group,
87% (95%CI 70%-100%) in theM-URDgroup, 80%
(95% CI 60%-100%) in the MM-URD group, and
95% (95%CI86%-100%) in theUCBgroup (P5 .18).
aGVHD
The cumulative incidence of grades II-IV aGVHD
for the entire cohort was 37% (95% CI 27%-47%) at
day 100. Grades II-IV aGVHD was higher in recipi-
ents of MM-URD transplants (75% [95% CI 49%-
100%]) when compared to MSD recipients (22%
[95% CI 8%-36%]), M-URD recipients (44% [95%
Table 1. Patient Demographics and Treatment Characteristics
MSD
M-URD (‘‘Well Matched’’ and
‘‘Partially Matched’’ URD)* MM-URD* UCB P-value
Number of patients 32 18 16 21
Age at diagnosis .36
< 1 year 1 (3%) 1 (6%) 3 (19%) 2 (10%)
$ 1 year 31 (97%) 17 (94%) 13 (81%) 19 (90%)
Median 4.6 years 3.4 years 5.4 years 4.2 years .13
T cell ALL 4 (13%) 0 3 (19%) 2 (10%) .33
Median Length of CR1 (range) 2.1 years (0.4-7.6) 2.0 years (0.6-3.9) 1.1 years (0.1-3.5) 2.2 years (0.1-5.6) .17
Median age at HCT (range) 8.0 years (3.1-17.9) 7.0 years (1.7-17.7) 6.9 years (0.9-17.2) 7.0 years (2.1-17.9) .44
Sex .91
Male 24 (75%) 13 (72%) 11 (69%) 14 (67%)
Female 8 (25%) 5 (28%) 5 (31%) 7 (33%)
Year of HCT <.01
1990-1994 10 (31%) 7 (39%) 8 (50%) 0
1995-1999 15 (47%) 9 (50%) 8 (50%) 6 (29%)
2000-2007 7 (22%) 2 (11%) 0 15 (71%)
Conditioning regimen <.01
Cy/TBI 12 (38%) 15 (83%) 12 (75%) 14 (67%)
Cy/TBI/Etop 20 (62%) 3 (17%) 4 (25%) 0
Cy/TBI/Flu 0 0 0 7 (33%)
Total number of nucleated cells
infused (108/kg)
Overall median (range) 2.0 (1.4-2.2) 2.0 (2.0-2.2) 2.0 (2.0-2.0) 0.33 (0.15-1.32) <.01
Non-T cell deplete median (range) n531 n 5 13 n 5 12 n 5 21
2.0 (1.4-2.2) 2.0 (2.0-2.2) 2.0 (2.0-2.0) 0.33 (0.15-1.32)
T cell deplete median (range) n 5 1 n 5 5 n 5 4 n 5 0
1.88 0.6 (0.27-0.7) 0.36 (0.25-0.73)
GVHD prophylaxis <.01
MTX based 31 (97%) 13 (72%) 12 (75%) 0
MP/CsA 0 0 0 14 (67%)
MMF/CsA 0 0 0 7 (22%)
T cell depletion 1 (3%) 5 (28%) 4 (25%) 0
Median length of follow-up among
survivors (range)
6.6 years (2.9-11.0) 9.3 years (3.4-14.5) 7.8 years (7.0-13.5) 4.1 years (1.0-7.8) .03
CR1 indicates first complete remission; Cy, cyclophosphamide; TBI, total body irradiation; Etop, etoposide; Flu, fludarabine; MTX, methotrexate; MP,
methylprednisone; CsA, cyclosporine A; MMF, mycophenolate mofetil; ALL, acute lymphoblastic leukemia; GVHD, graft-versus-host disease; UCB,
umbilical cord blood; MSD, matched sibling donor; M, matched; MM, mismatched; HCT, hematopoietic cell transplantation.
*Matching for URDs are according to Weisdorf et al. [12] matching algorithm.
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0%-22%) (P\ .01). Using the sibling donor group
as the reference category in a multiple regression anal-
ysis (Table 2), theMM-URD group had a significantly
higher risk of grades II-IV aGVHD (relative risk [RR]
5.8, 95% CI 2.3%-13.2%, P\ .01). Despite the high
degree of donor-recipient MM, the risk of GVHD af-
ter UCB transplant was not significantly different from
that observed in recipients of MSD marrow (Table 2).
The cumulative incidence of grades III-IV aGVHD
for the entire cohort was 15% (95% CI 8%-22%) atTable 2. Multivariate Analysis of Acute and Chronic GVHD
Donor type
Relative Risk of Grades II-IV
Acute GVHD (95% CI) P-Value
Relative Risk
Acute GVH
MSD* 1.0 1
M-URD 2.4 (0.9-6.5) .08 3.9 (0
MM-URD 5.8 (2.3-13.2) <.01 5.6 (1
UCB 1.2 (0.4-3.6) .80 1.6 (0
MSD indicates matched related sibling; M-URD, matched unrelated donor; M
confidence interval, GVHD, graft-versus-host disease.
The above model is the result of multiple regression analysis on GVHD after te
conditioning, GVHD prophylaxis, cytomegalovirus (CMV) serostatus, age, leng
*Reference category.day 100. In multiple regression analysis, there was
a higher risk of grade III-IV aGVHD in recipients of
MM-URD grafts (RR 5.6, 95% CI 1.1%-27.8%,
P 5 .03). The risk in recipients of M-URD and UCB
grafts were similar to that observed in recipients of
MSD marrow (Table 2).
cGVHD
Overall, only 8 patients developed cGVHD (3 lim-
ited, 5 extensive) by 1 year after transplant for an inci-
dence of 9% (95%CI 3%-15%). There were 2 patientsof Grades III-IV
D (95% CI) P-Value
Relative Risk of Chronic
GHVD (95% CI) P-Value
.0 1.0
.7-20.3) .11 2.8 (0.5-15.8) .25
.1-27.8) .03 2.2 (0.3-15.2) .44
.2-11.7) .63 0.8 (0.1-8.3) .83
M-URD, mismatched unrelated donor, UCB, umbilical cord blood; CI,
sting the following independent variables: donor type, sex, pretransplant
th of first remission, and type of ALL (T cell versus B cell).
1090 Biol Blood Marrow Transplant 15:1086-1093, 2009A. R. Smith et al.(6%) in the MSD group, 3 (17%) in the M-URD
group, 2 (13%) in the MM-URD group, and 1 (5%)
in the UCB group who developed cGVHD. In multi-
ple regression analysis there was no difference in RR
among the 4 groups (Table 2). Three of the 8 subjects
diagnosed with cGVHDdied during the follow-up pe-
riod. The 5 remaining patients are alive, symptom free,
and are no longer on immunosuppressive therapy.LFS
Probability of LFS for the entire cohort of patients
was 45% (95% CI 35%-65%) and 40% (95% CI
30%-50%) at 1 and 5 years, respectively. By donor
type, the 5-year LFS was 41% (95% CI 24%-68%)
in recipients of a MSD, 57% (95% CI 35%-80%) in
recipients of aM-URD, 19% (95%CI 5%-40%) in re-
cipients of aMM-URD, and 43% (95%CI 23%-63%)
in recipients of UCB (P5 .05) (Figure 1a). For patients
with a CR1$3 years, 5-year LFS was significantly bet-
ter at 56% (95% CI 35%-73%) compared to 33%
(95% CI 21%-45%) in those patients with a CR1\3
year (P 5 .02). Patients with T cell ALL (n 5 9) had
0% LFS at 5 years compared to 46% in those with
pre-B cell ALL (P 5 .04). In multivariate regression
analysis MM-URD recipients had a 3.2 times
increased relative risk of relapse or death (P 5 .01).Years post HCT
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Figure 1. Probability of (a) LFS and (b) relapse by HSC source. Legend:
(a) probability of LFS by HSC source. The probability at 5 years was 0.41
in recipients of MSD, 0.57 in recipients of M-URD, 0.19 in recipients of
MM-URD, and 0.43 in recipients of UCB. (b) Probability of relapse by
HSC source. The probability at 5 years was 0.50 in recipients of MSD,
0.17 in recipients of M-URD, 0.06 in recipients of MM-URD, and 0.33
in recipients of UCB.In addition, patients with a CR1 .3 years or grades
II-IV aGVHD had less than half the relative risk of re-
lapse or death (P\ .01 and.02, respectively) (Table 3a).
Relapse
A total of 27 patients had disease recurrence after
HCT for an overall incidence of 31% (95% CI
21%-41%) at 5 years. In univariate analysis, the prob-
ability of relapse at 5 years was 50% (95% CI 31%-
71%) in those with an MSD, 17% (95% CI 0%-33%)
in those with an M-URD, 6% (95% CI 0%-16%) in
those with an MM-URD, and 33% (95% CI 13%-
53%) after UCB transplant (P 5 .17) (Figure 1b). For
patients with aCR1$3 years, the probability of relapse
at 5 years was 16% (95% CI 2%-29%) compared to
38% (95%CI 25%-51%) in those with aCR1\3 years
(P\ .01). In multivariate regression analysis, the only
factors that had a significant impact on the risk of re-
lapse were the development of grade II-IV aGVHD
(RR 0.2, 95% CI 0.1%-0.8%, P 5 .03) and having
a CR1 of .3 years (RR 0.2, 95% CI 0.1%-0.7%, P 5
.01). Donor type did not have a significant impact on
the risk of relapse (Table 3b).
Mortality
Incidence of TRM at 1 year for the entire cohort
was 26% (95% CI 17%-35%). TRM was higher in
those with an MM-URD (69%, 95% CI 43%-95%)
compared to those with MSD (9%, 95% CI
0%-19%), M-URD (22%, 95% CI 4%-40%), and
UCB grafts (24%, 95% CI 6%-42%). When examin-
ing the contributing causes of death by donor source,
disease recurrence was the most frequent cause in re-
cipients of MSD marrow (72% [n 5 14]) and UCB
(58% [n 5 7]) compared to that in recipients of
M-URD (33% [n 5 3]) and MM-URD marrow (8%
[n 5 1]) (P\ .01). aGVHD was more common in re-
cipients of MM-URD (69% [n 5 9]) compared to
those who received MSD (12% [n 5 2]), M-URD
(38% [n5 3]), or UCB (25% [n5 3]) grafts (P5 .06).DISCUSSION
We have summarized the transplant results at
a single center comparing transplant outcomes by
HSC source specifically for children with ALL in
CR2. Although the number of patients studied is lim-
ited, our results suggest that transplant outcomes are
remarkably similar in recipients of MSD, M-URD,
and UCB grafts. Specifically, there were no obvious
differences in LFS, risk of relapse, and most impor-
tantly, risk of early TRM.
Our results also show that patients receiving
MM-URD grafts have a higher risk of developing
grades II-IV aGVHD than theMSD group. Such find-
ings are not surprising given the association of HLA
matching and GVHD [19]. Although there was a trend
Table 3. Multivariate Analysis of (a) Leukemia Free Survival
and (b) Relapses
a)
Relative Risk of
Relapse or Mortality
(95% CI) P-Value
Donor type
MSD* 1.0
M-URD 1.1 (0.5-2.5) .89
MM-URD 3.2 (1.3-7.7) .01
UCB 1.2 (0.6-2.4) .68
Length of first remission
<1 Year* 1.0
1-3 Years 0.6 (0.3-1.1) .07
>3 Years 0.3 (0.2-0.8) <.01
Grade II-IV acute GVHD
No* 1.0
Yes 0.4 (0.2-0.9) .02
MSD indicates matched related sibling; M-URD, matched unrelated
donor; MM-URD, mismatched unrelated donor, UCB, umbilical cord
blood; CI, confidence interval, GVHD, graft-versus-host disease.
*Reference category.
b)
Relative Risk of Relapse
(95% CI) P-Value
Donor type
MSD* 1.0
M-URD 0.5 (0.1-1.8) .28
MM-URD 0.5 (0.1-5.2) .60
UCB 0.8 (0.3-2.1) .71
Length of First Remission
< 1 Year* 1.0
1-3 Years 0.7 (0.3-1.8) .42
>3 Years 0.2 (0.1-0.7) .01
Grade II-IV Acute GVHD
No* 1.0
Yes 0.2 (0.1-0.8) .03
MSD indicates matched related sibling; M-URD, matched unrelated do-
nor; MM-URD, mismatched unrelated donor, UCB, umbilical cord
blood; CI, confidence interval, GVHD, graft-versus-host disease.
Legend: the above model is the result of multiple regression analysis on
GVHD after testing the following independent variables: donor type,
sex, pretransplant conditioning, GVHD prophylaxis, CMV serostatus,
age, length of first remission, and type of ALL (T cell versus B cell).
*Reference category.
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did not reach statistical significance. When compared
to the MSD group, UCB recipients did not differ in
the risk of aGVHD despite considerable HLA
disparity. Although there is a higher risk of aGVHD
in recipients of MM-URD BM and a trend toward
a higher risk in recipients of M-URD marrow, in-
creased mortality from the GVHD was only observed
in the MM-URD recipients. In addition, those pa-
tients who developed grades II-IV aGVHD had a sig-
nificantly lower risk of relapse than those withGVHD.
The overall incidence of cGVHD at 1 year posttrans-
plant (9%) in our cohort of patients is less than what
would be expected based on the literature [14,20],
and we did not observe a difference in cGVHD based
on HSC source. Such results are encouraging becauserisks of TRM and debilitating complications of
cGVHD have been the principal reasons for delayed
referral for URD HCT, whether from a marrow or
UCB donor.
The improved outcome after alternate donor
transplant for ALL in CR2 that we and others
[21-23] have observed is likely secondary to better sup-
portive care measures and unrelated donor selection
strategies. In recent years, the adverse effect of
HLA-C mismatching [24] and the importance of
high-resolution allele level typing in unrelated donor
marrow transplantation has been firmly established
[25]. The prospective addition of these HLA typing
strategies may even further improve outcomes seen
after alternative donor HCT.
Advantages of this study include the fact that it is sin-
gle-centerdatawithhomogenouspatient selectioncrite-
ria and supportive care measures. Consequently,
though, the sample size is relatively low, resulting in di-
minished power. In addition, because the study period
spanned a number of years, the standards for HLA
matching shifted to include allele level typing and typing
at HLA-C, which makes analyses based on matching
more difficult.
Another limitation of this study is the absence of
data on health-related quality of life (HRQL).
Although it could be argued that HRQL may be
poorer in recipients of unrelated donor transplants
compared to that after an MSD transplant, there are
few studies to date in long-term survivors specifically
addressing this hypothesis. There are many reports,
though, that show that the major contributor to de-
creased HRQL after HCT is the presence of cGVHD
[14,26,27]. Although our analysis clearly demonstrates
a higher incidence of aGVHD in recipients of MM-
URDmarrow, nearly all survivors at 2 years were off im-
mune suppressive therapy. Furthermore, the incidence
of cGVHD was only 9%, with no difference between
sources. This similarity in the cumulative incidence
cGVHD and prevalence of immune suppressive ther-
apy use between groups would suggest that long-
term HRQL is also likely similar. Future trials,
though, should include HRQL assessments to more
accurately determine if true differences exist between
the groups.
One remaining question is whether a particular
HSC source is optimal. Recent reports indicate
similar, if not improved, LFS with HLA matched or
mismatched UCB for children with acute leukemia
[28]. In addition, although the mechanism is unclear,
preliminary data suggest that using more than
1 UCB unit may decrease the risk of relapse in patients
with acute leukemia [29]. This strategy is currently
being tested in a multicenter trial where patients are
randomized to receive either a single or double UCB
transplant. Although there are advantages and disad-
vantages to each alternate donor source, timing of
1092 Biol Blood Marrow Transplant 15:1086-1093, 2009A. R. Smith et al.availability, prior infectious disease screening, and the
ability to readily find a suitable donor for patients of all
ethnicities are important factors to consider in trans-
plantation for malignant diseases like acute leukemia.
Compared to BMUCB offers the advantages of imme-
diate availability and a high probability of finding
a suitable match regardless of the ethnicity of the pa-
tient [28,30].
In the absence of a prospective, randomized trial
that would compare 5-year LFS and HRQL in patients
with ALL in CR2 treated with allogeneic HCT (MSD
versus M-URD versus UCB) and conventional chemo-
therapy, we will have to rely on retrospective analyses
from single centers or registries. Although registry
data benefits from greater patient numbers, single-cen-
ter results benefit from less heterogeneity in patient se-
lection criteria and supportive care measures between
groups. Given the nature of the disease and precon-
ceived notions regarding each treatment approach, ran-
domization is even more difficult, as exemplified by the
Children’s Cancer Group study in which patients with-
out an MSD were to be randomized to maintenance
chemotherapy, autologous HCT, or alternate donor
HCT (M-URD or haploidentical) [31]. Although the
study design was appropriate, many enrolled patients
later refused the randomization because of patient and
physician preferences, thereby limiting the interpreta-
tion of the results. This study and others [21-23] sug-
gesting similar outcomes in patients with ALL in CR2
regardless of donor source, should reassure pediatric
oncologists and support the development and imple-
mentation of such a randomized trial. In the meantime,
additional retrospective analyses are needed in this pa-
tient population comparing alternate donor HCT to
MSD HCT in larger numbers of patients.
With our current standards of HLA typing and
continued advances in supportive care measures, this
study supports further investigation of the use of
URD HCT in children with ALL in CR2, and
suggests that the timing of HCT in these children
should be based primarily on the risk of relapse with
conventional chemotherapy and not on the type of
donor available.ACKNOWLEDGMENTS
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